# cancer_prostate
Multiomic Data Analytics Integration in Prostate Cancer

Summary
We plan to perform a multi-omics technologies analysis of data generated from genomic, transcriptomic, epigenomic, proteomic and metabolomics studies, in patients with prostate cancer. The aim of the study is to uncover the mechanism of the tumor progression, identifying distinct tumor subtypes and ultimately finding new prostate cancer biomarkers for effective prognosis, prevention, and therapy and monitoring of drug responses.

Introduction

Background  
Prostate cancer (PCa), a hormone-dependent oncological disease, is a deadly disease for men associated with heterogeneous clinical outcome. Clinically, it is characterized by indolent phenotypes, rapid progression and aggressive metastatic disease (Sathianathen et al., 2018). Among cancer worldwide, PCa as a common male tumor has an incidence of second lung cancer (Siegel et al., 2019). This neoplastic process according to the Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) has become a leading cause of cancer worldwide, with over 1.4 million new cases and a total of 375,000 deaths in 2020 (Sung et al., 2020). The heterogeneity of the disease calls for the use of all types of omics data necessary to promote precision medicine. PCa progression is slow compared to other tumors but still harms patient long-term health (Eggener et al., 2015). The multifocal and heterogeneity of primary PCa is associated with poor prognosis (wang et al., 2018), this means that intervention for patients with metastasis are still urgently needed. While patients with slow disease progression show better outcomes, patients with higher aggressiveness show worse treatment prognosis and current clinicopathological indicators do not distinguish well between patients based on their outcomes at the initial stage of the disease (Zhang et al., 2020). Consequently, efficient identification of the risk level of prostate cancer patients and precise therapeutic targets has always been an important equation to solve in PCa. The occurrence and development of PCa is related to multisystem and multilevel pathological changes. Studies at single omics level often have limitations, while combined analysis of multiple omics data can better and more comprehensively develop targeted markers for PCa therapy. A study done by Sinha et al PCa multi omics revealed that proteomics features were significantly more informative for biochemical recurrence prediction than genomic, epigenomics or transcriptomics (Sinha et al., 2019). As much as the single technologies have identified and shed light on the mechanisms of the tumor progression, subtypes and finding new treatment targets, a holistic molecular perspective of the mechanisms, prospective biomarkers and drug targets and responses can only be uncovered when a systems biology approach is adopted. Hence in the current study we shall be using good quality multi-omics data sets from public databases to gain a better understanding of tumor progression, subtyping and finding novel biomarkers that potentially address individual variations in drug responses among prostate cancer patients. In addition, we shall also provide a simplified protocol for routine integration of multi-omics data sets to answer biological questions.

Research question: Is there any promising biomarker for better management of Prostate cancer in African men descent using a multi omics approach?

Problem statement 

The study of single omics has played an irreplaceable role in the diagnosis and treatment of diseases. However, with the improvement of research means and research demands, single omics may not be comprehensive enough, and changes at a single level may not necessarily represent the overall changes of the organism. For example, only 10%–20% of changes in the transcriptome correlate with proteomic data (Mertins et al., 2016). The heterogeneous clinical outcome status associated with prostate cancer can be uncovered using all single omics approaches at once in order to provide most efficient, specifics and sensitives novel metabolic signatures for a better clinical management of prostate cancer patients.  
Although there is a lack of data and bioinformatics skills in the country, the prostate cancer multi omics approach should be performed in African men with available data to understand the entire mechanism of the cancer for new biomarker discovery for early, comfortable and efficient screening, diagnostics and treatment. 

Justification

In the field of precision oncology, genomics approaches, and, more recently, other omics analyses have helped reveal several key mechanisms in cancer development, treatment resistance, and recurrence risk, and several of these findings have been implemented in clinical oncology to help guide treatment decisions. truly integrated multi-omics analyses have not been applied widely, preventing further advances in precision medicine (Olivier et al., 2019). Despite the efforts to improve the diagnosis, risk stratification, and treatment of PCa patients, a number of challenges still need to be addressed (Gómez-Cebrián et al., 2022). Studies have shown that proteomics data explain better the complexity of prostate cancer. This study is going to apply multi omics approach data analysis using two omics data genomics and proteomics to explain PCa mechanism and provide a simplified and standardized tool for its implementation in patient management. 

Objectives:  

Main objective: 
Identify African descent biomarkers associated with Prostate cancer using multi omics available data for better management of patients. 

Specifics objectives: 
1.Explain prostate cancer biological complexity using multi omics approach
2.Provide a simplified and standardized African specific prostate cancer management 
Primary Outcome Measures 
1.	Genetic profiling results - Mutation identified via whole-genome sequencing will be recorded.
2.	Transcriptional profiling results - Determining the transcriptomic information of prostate cancer
3.	Epigenomic profiling results - Determining the epigenomic status of specific genes
4.	Proteomic profiling results – determine the proteomic information of the prostate cancer
5.	Metabolomic profiling results – determine the profiles of the metabolites in prostate cancer patients


References 

1.Danwang, C., Temgoua, M. N., Agbor, V. N., Tankeu, A. T., & Noubiap, J. J. (2017). Epidemiology of venous thromboembolism in Africa: a systematic review. Journal of Thrombosis and Haemostasis, 15(9), 1770-1781. 
2. Rahman, F., Kwan, G. & Benjamin, E. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 11, 639–654 (2014). https://doi.org/10.1038/nrcardio.2014.118 

 3.Wendelboe, A. M., McCumber, M., Hylek, E. M., Buller, H., Weitz, J. I., Raskob, G., ... & Ozaki, Y. (2015). Global public awareness of venous thromboembolism. Journal of Thrombosis and Haemostasis, 13(8), 1365-1371. 

 3.Majonga, E. D., Rehman, A. M., Simms, V., Mchugh, G., Mujuru, H. A., Nathoo, K., Odland, J. O., Patel, M. S., Kaski, J. P., & Ferrand, R. A. (2018). High prevalence of echocardiographic abnormalities in older HIV-infected children taking antiretroviral therapy. AIDS (London, England), 32(18), 2739–2748. https://doi.org/10.1097/QAD.0000000000002031 

4.Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., ... & COMMAND VTE Registry Investigators. (2018). Anticoagulation therapy for venous thromboembolism in the real world―From the COMMAND VTE Registry―. Circulation 
5.Morillo, C. A., Banerjee, A., Perel, P., Wood, D., & Jouven, X. (2017). Atrial fibrillation: the current epidemic. Journal of geriatric cardiology: JGC, 14(3), 195–203. https://doi.org/10.11909/j.issn.1671-5411.2017.03.011 
6.Magnocavallo, M., Bellasi, A., Mariani, M. V., Fusaro, M., Ravera, M., Paoletti, E., ... & Di Lullo, L. (2021). Thromboembolic and bleeding risk in atrial fibrillation patients with chronic kidney disease: role of anticoagulation therapy. Journal of Clinical Medicine, 10(1), 83. 

7.Ndadza, A., Muyambo, S., Mntla, P., Wonkam, A., Chimusa, E., Kengne, A. P., ... & Dandara, C. (2021). Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm. J Thromb Haemost, 19, 2957-2973. 

8.Semakula, J. R., Mouton, J. P., Jorgensen, A., Hutchinson, C., Allie, S., Semakula, L., ... & Cohen, K. (2020). A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PloS one, 15(1), e0227458. 

9.Kow, C.S., Sunter, W., Bain, A., Zaidi, S.T.R., and Hasan, S.S. (2020). Management of outpatient warfarin therapy amid COVID-19 pandemic: a practical guide. American Journal of Cardiovascular Drugs, 20(4), 301-309.
10.Sjögren, V., Grzymala-Lubanski, B., Renlund, H., Friberg, L., Lip, G. Y., Svensson, P. J., & Själander, A. (2015). Safety and efficacy of well managed warfarin. Thrombosis and haemostasis, 113(06), 1370-1377. 
11.Leminen, A., Pyykönen, M., Tynkkynen, J., Tykkyläinen, M., & Laatikainen, T. (2019). Modeling patients’ time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants. BMC Health Services Research, 19(1), 1-13. 
12.Dean, L. (2018). Warfarin therapy and VKORC1 and CYP genotype. 
13.Patel, S., Singh, R., and Preuss, C.V. (2021). Warfarin. Treasure Island (FL), StatPearls Publishing, Available from: https://www.ncbi.nlm.nih.gov/books/NBK470313/.
14.Johnson, J. A., Gong, L., Whirl‐Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., ... & Altman, R. B. (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clinical Pharmacology & Therapeutics, 90(4), 625-629. 
15.Dean Julie, A.Johnson., Kelly, E. Caudle., Li, Gong., Michelle, Whirl-Carrillo., Michael, C. Stein., Stuart, A. Scott., Ming, Ta. Michael Lee., Brian, F. Gage., Stephen, E. Kimmel., Minoli, A. Perera., Jeffrey, L. Anderson., Munir, Pirmohamed., Teri, E. Klein., Nita,A.Limdi., Larisa, H. Cavallari., Mia, Wadelius. (2017). Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmavogenetics-guided warfarin dosing: 2017 update
16.J.A. Johnson, K.E. Caudle, L. Gong, M. WhirlCarrillo, C.M. Stein, S.A. Scott, M.T. Lee, B.F.Gage, S.E. Kimmel, M.A. Perera, J.L. Anderson, M. Pirmohamed, T.E. Klein, N.A. Limdi, LH. Cavallari, M. Wadelius Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update Clin Pharmacol Ther, 102 (2017), pp. 397-404

17.Drozda, K., Pacanowski, M. A., Grimstein, C. and Zineh, I. (2018). Pharmacogenetic
Labeling of FDA-Approved Drugs. JACC: Basic to Translational Science, 3(4), 545–549. doi: 10.1016/j.jacbts.2018.06.001  
18.Mostafa, S., Kirkpatrick, C.M., Byron, K. and Sheffield, L. (2019). An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. Journal of Neural Transmission, 126(1), 5-18. 
19.Pereira, L., Mutesa, L., Tindana, P., & Ramsay, M. (2021). African genetic diversity and adaptation inform a precision medicine agenda. Nature Reviews Genetics, 22(5), 284-306. 
20.Adehin, A., Bolaji, O. O., & Kennedy, M. A. (2017). Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population. Drug metabolism and pharmacokinetics, 32(3), 189-191. 
21. Dean Julie, A.Johnson., Kelly, E. Caudle., Li, Gong., Michelle, Whirl-Carrillo., Michael, C. Stein., Stuart, A. Scott., Ming, Ta. Michael Lee., Brian, F. Gage., Stephen, E. Kimmel., Minoli, A. Perera., Jeffrey, L. Anderson., Munir, Pirmohamed., Teri, E. Klein., Nita,A.Limdi., Larisa, H. Cavallari., Mia, Wadelius. (2017). Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmavogenetics-guided warfarin dosing: 2017 update
22.Alberts, Marks., Chen, Y.-W., Lin, J. H., Kogan, E., Twyman, K., & Milentijevic, D. (2019). Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin. Stroke. doi:10.1161/strokeaha.119.025554 

23.Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association.Circulation. 2017; 135:e146–e603. doi: 10.1161/CIR.0000000000000485 

24.Noubiap, J. J., & Nyaga, U. F. (2019). A review of the epidemiology of atrial fibrillation in sub‐Saharan Africa. Journal of Cardiovascular Electrophysiology, 30(12), 3006-3016. 
 
25.World Health Organization. Global health estimates 2016, deaths by cause, age, sex, by country and by region, 2000–2016<http://www.who.int/healt hinfo/ global_burden_disea se/GHE20 16_Deaths_2016-count ry.xls?ua=1> (2018). 

26.Ndadza, A., Muyambo, S., Mntla, P., Wonkam, A., Chimusa, E., Kengne, A. P., ... & Dandara, C. (2021). Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm. J Thromb Haemost, 19, 2957-2973. 

27.De Caterina, R., Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., ... & Weitz, J. I. (2016). Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 115(04), 685-711. 

28.Mouton, J.P. et al. Adverse drug reactions causing admission to medical wards: a cross-sectional survey at 4 hospitals in South Africa. Medicine (Baltimore) 95, e3437 (2016). 

29.Morillo, C. A., Banerjee, A., Perel, P., Wood, D., & Jouven, X. (2017). Atrial fibrillation: the current epidemic. Journal of geriatric cardiology : JGC, 14(3), 195–203. https://doi.org/10.11909/j.issn.1671-5411.2017.03.011 
30.Ndadza, A., Thomford, N. E., Mukanganyama, S., Wonkam, A., Ntsekhe, M., & Dandara, C. (2019). The genetics of warfarin dose–response variability in Africans: an expert perspective on past, present, and future. Omics: a journal of integrative biology, 23(3), 152-166. 
31.Jorgensen, A. L., Prince, C., Fitzgerald, G., Hanson, A., Downing, J., Reynolds, J., ... & Pirmohamed, M. (2019). Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. BMC medicine, 17(1), 1-11. 
32.Clark, N. P., Witt, D. M., Davies, L. E., Saito, E. M., McCool, K. H., Douketis, J. D., ... & Delate, T. (2015). Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA internal medicine, 175(7), 1163-1168.

33.Brieger, D., Amerena, J., Attia, J. R., Bajorek, B., Chan, K. H., Connell, C., ... & Zwar, N. A. (2018). National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Medical Journal of Australia, 209(8), 356-362. 

34.Pratt, V. M., Cavallari, L. H., Del Tredici, A. L., Hachad, H., Ji, Y., Kalman, L. V., ... & Weck, K. E. (2020). Recommendations for clinical warfarin genotyping allele selection: a report of the Association for Molecular Pathology and the College of American Pathologists. The Journal of Molecular Diagnostics, 22(7), 847-859. 

35.Pratt, V. M., Del Tredici, A. L., Hachad, H., Ji, Y., Kalman, L. V., Scott, S. A., & Weck, K. E. (2018). Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. The Journal of Molecular Diagnostics, 20(3), 269-276. 

36.M.L. Alvarellos, K. Sangkuhl, R. Daneshjou, M. Whirl-Carrillo, R.B. Altman, T.E. Klein
PharmGKB summary: very important pharmacogene information for CYP4F2 Pharmacogenet Genomics, 25 (2015), pp. 41-47

37.J.A. Johnson, K.E. Caudle, L. Gong, M. WhirlCarrillo, C.M. Stein, S.A. Scott, M.T. Lee, B.F.Gage, S.E. Kimmel, M.A. Perera, J.L. Anderson, M. Pirmohamed, T.E. Klein, N.A. Limdi, L.H. Cavallari, M. Wadelius Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update Clin Pharmacol Ther, 102 (2017), pp. 397-404

38.E. Danese, S. Raimondi, M. Montagnana, A. Tagetti, T. Langaee, P. Borgiani, et al.
Effect of CYP4F2, VKORC1, and CYP2C9 in influencing coumarin dose: a single-patient data meta-analysis in more than 15,000 individuals Clin Pharmacol Ther, 105 (2019), pp. 1477-1491

39. Lip, G. Y., Freedman, B., De Caterina, R., & Potpara, T. S. (2017). Stroke prevention in atrial fibrillation: past, present and future. Thrombosis and haemostasis, 117(07), 1230-1239. 

40. Fohner, A. E., Robinson, R., Yracheta, J., Dillard, D. A., Schilling, B., Khan, B., ... & Thummel, K. E. (2015). Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenetics and genomics, 25(7), 343. 

41. Shaw, K., Amstutz, U., Kim, R. B., Lesko, L. J., Turgeon, J., Michaud, V., ... & Carleton, B. C. (2015). Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy. Therapeutic drug monitoring, 37(4), 428-436. 

42. Barkhudaryan, A., Doehner, W., & Scherbakov, N. (2021). Ischemic Stroke and Heart Failure: Facts and Numbers. An Update. Journal of Clinical Medicine, 10(5), 1146. 

43. Perera, M. A., Cavallari, L. H., Limdi, N. A., Gamazon, E. R., Konkashbaev, A., Daneshjou, R., ... & Johnson, J. A. (2013). Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. The Lancet, 382(9894), 790-796.
 
44.Radouani, F., Zass, L., Hamdi, Y., Rocha, J. D., Sallam, R., Abdelhak, S., ... & Mulder, N. (2020). A review of clinical pharmacogenetics studies in African populations. Personalized medicine, 17(2), 155-170. 

45.Muyambo, S., Ndadza, A., Soko, N. D., Kruger, B., Kadzirange, G., Chimusa, E., ... & Dandara, C. (2022). Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes. Omics: a journal of integrative biology, 26(1), 35-50. 

46.Safari, S., & Yousefifard, M. (2021). A guideline for the prevention and treatment of thromboembolism in COVID-19 patients. Journal of Emergency Practice and Trauma, 7(1), 4-6. 
47.Patel, S., Singh, R., Preuss, C. V., & Patel, N. (2021). Warfarin. StatPearls [Internet]. 

48.Messé, S. R., Gronseth, G. S., Kent, D. M., Kizer, J. R., Homma, S., Rosterman, L., ... & Kasner, S. E. (2020). Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the Guideline Subcommittee of the American Academy of Neurology. Neurology, 94(20), 876-885. 

49.Li, X., Li, D., Wu, J. C., Liu, Z. Q., Zhou, H. H., & Yin, J. Y. (2019). Precision dosing of warfarin: open questions and strategies. The Pharmacogenomics Journal, 19(3), 219-229. 

50. Daly, A. K., Rettie, A. E., Fowler, D. M., & Miners, J. O. (2018). Pharmacogenomics of CYP2C9: functional and clinical considerations. Journal of personalized medicine, 8(1), 1.   
 
 
Team schedule
Dataset 
Team: Glory, Page, David enoma
Literature review
Team: Lawrence and Marie 
Scripting
Team: Page, Glory and Marie 
Writing for progress: 
Team: Marie 
Slides
Team: Glory and Lawrence
Manuscript
Team: Lawrence and David Juma
Workflow
Team: Page, Vincent  

